Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $15
Vor Biopharma, Inc. +1.71%
Vor Biopharma, Inc. VOR | 15.43 | +1.71% |
Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:
VOR) with a Neutral and raises the price target from $9 to $15.
